Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free KMTS Stock Alerts

Kestra Medical Technologies (KMTS) Financials

Kestra Medical Technologies logo
$22.28 -0.96 (-4.11%)
As of 03:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Kestra Medical Technologies

Annual Income Statements for Kestra Medical Technologies

This table shows Kestra Medical Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2025 2026
Period end date 4/30/2024 4/30/2025 4/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -101 -126 -132
Consolidated Net Income / (Loss)		 -94 -114 -132
Net Income / (Loss) Continuing Operations		 -94 -114 -132
Total Pre-Tax Income 		-94 -114 -131
Total Operating Income		 -85 -106 -135
Total Gross Profit		 0.36 24 49
Total Revenue		 28 60 95
Operating Revenue		 28 60 95
Total Cost of Revenue		 27 36 46
Operating Cost of Revenue		 27 36 46
Total Operating Expenses		 85 131 184
Selling, General & Admin Expense		 70 115 164
Research & Development Expense		 15 16 19
Total Other Income / (Expense), net		 -9.03 -7.30 3.42
Interest Expense		 6.23 7.73 7.55
Interest & Investment Income		 0.00 3.20 8.35
Other Income / (Expense), net		 -2.80 -2.77 2.62
Income Tax Expense		 0.02 0.14 0.29
Preferred Stock Dividends Declared		 6.72 12 0.00
Basic Earnings per Share		 ($5.07) ($5.13) ($2.43)
Weighted Average Basic Shares Outstanding		 19.89M 24.58M 54.18M
Diluted Earnings per Share		 ($5.07) ($5.13) ($2.43)
Weighted Average Diluted Shares Outstanding		 19.89M 24.58M 54.18M
Weighted Average Basic & Diluted Shares Outstanding		 - 51.35M 58.60M

Quarterly Income Statements for Kestra Medical Technologies

This table shows Kestra Medical Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q3 2026
Period end date 7/31/2024 10/31/2024 1/31/2024 7/31/2025 10/31/2025 1/31/2025 4/30/2025 1/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -22 -24 -23 -26 -33 -25 -43 -34
Consolidated Net Income / (Loss)		 -20 -20 -22 -26 -33 -22 -34 -34
Net Income / (Loss) Continuing Operations		 -20 -21 -22 -26 -33 -22 -33 -34
Total Pre-Tax Income 		-20 -21 -22 -26 -33 -22 -33 -34
Total Operating Income		 -18 -19 -20 -29 -32 -21 -25 -35
Total Gross Profit		 4.20 5.83 0.88 8.85 11 6.55 -2.61 13
Total Revenue		 13 15 8.28 19 23 15 2.79 25
Operating Revenue		 13 15 8.28 19 23 15 2.79 25
Total Cost of Revenue		 8.58 8.88 7.40 11 11 8.54 5.40 12
Operating Cost of Revenue		 8.58 8.88 7.40 11 11 8.54 5.40 12
Total Operating Expenses		 23 25 21 38 43 27 23 48
Selling, General & Admin Expense		 19 21 17 34 38 24 19 43
Research & Development Expense		 3.40 3.51 3.74 4.00 4.88 3.35 3.42 4.97
Total Other Income / (Expense), net		 -1.89 -1.48 -1.66 3.09 -1.00 -1.14 -8.25 0.63
Interest Expense		 1.87 2.32 1.65 1.91 1.90 1.78 2.14 1.89
Interest & Investment Income		 0.04 0.88 0.00 2.17 1.80 0.63 -1.39 2.16
Other Income / (Expense), net		 -0.05 -0.04 -0.01 2.83 -0.89 0.02 -4.72 0.36
Income Tax Expense		 0.01 0.01 0.01 0.03 0.03 0.02 0.05 0.04
Preferred Stock Dividends Declared		 2.38 3.32 1.81 0.00 0.00 3.32 9.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.44 -0.25 0.00 0.00 0.00 -0.25 - 0.00
Basic Earnings per Share		 ($1.12) ($1.19) ($1.18) ($0.50) ($0.64) ($1.25) ($2.74) ($0.61)
Weighted Average Basic Shares Outstanding		 19.89M 19.89M 19.89M 51.30M 51.38M 19.89M 24.58M 55.85M
Diluted Earnings per Share		 ($1.12) ($1.19) ($1.18) ($0.50) ($0.64) ($1.25) ($2.74) ($0.61)
Weighted Average Diluted Shares Outstanding		 19.89M 19.89M 19.89M 51.30M 51.38M 19.89M 24.58M 55.85M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 51.45M 58.35M 51.35M 51.35M 58.37M

Annual Cash Flow Statements for Kestra Medical Technologies

This table details how cash moves in and out of Kestra Medical Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2025 2026
Period end date 4/30/2024 4/30/2025 4/30/2026
Net Change in Cash & Equivalents		 -6.74 229 -138
Net Cash From Operating Activities		 -72 -78 -82
Net Cash From Continuing Operating Activities		 -72 -78 -82
Net Income / (Loss) Continuing Operations		 -94 -114 -132
Consolidated Net Income / (Loss)		 -94 -114 -132
Depreciation Expense		 12 7.97 8.71
Amortization Expense		 0.61 1.40 1.77
Non-Cash Adjustments To Reconcile Net Income		 5.82 33 37
Changes in Operating Assets and Liabilities, net		 3.90 -6.14 1.94
Net Cash From Investing Activities		 -12 -23 -203
Net Cash From Continuing Investing Activities		 -12 -23 -203
Purchase of Property, Plant & Equipment		 -12 -23 -35
Purchase of Investments		 - 0.00 -163
Other Investing Activities, net		 -0.00 -0.37 -5.34
Net Cash From Financing Activities		 78 330 147
Net Cash From Continuing Financing Activities		 78 330 147
Repayment of Debt		 -41 0.00 0.00
Repurchase of Preferred Equity		 0.00 -3.52 0.00
Repurchase of Common Equity		 0.00 -3.22 -2.47
Issuance of Debt		 45 0.00 0.00
Issuance of Preferred Equity		 75 103 0.00
Issuance of Common Equity		 0.00 216 149
Other Financing Activities, net		 -0.80 18 0.27
Cash Interest Paid		 3.63 4.85 5.65
Cash Income Taxes Paid		 -0.03 0.08 0.01

Quarterly Cash Flow Statements for Kestra Medical Technologies

This table details how cash moves in and out of Kestra Medical Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q4 2026
Period end date 7/31/2024 10/31/2024 4/30/2024 7/31/2025 10/31/2025 1/31/2025 4/30/2025 4/30/2026
Net Change in Cash & Equivalents		 92 -23 -6.87 -36 -26 108 183 -192
Net Cash From Operating Activities		 -17 -18 -15 -26 -18 -8.94 -24 -19
Net Cash From Continuing Operating Activities		 -17 -18 -15 -26 -18 -8.94 -24 -19
Net Income / (Loss) Continuing Operations		 -20 -21 -22 -26 -33 -4.09 -51 -39
Consolidated Net Income / (Loss)		 -20 -21 -22 -26 -33 -4.09 -51 -39
Depreciation Expense		 2.38 1.87 3.50 2.03 2.37 1.73 1.84 2.33
Amortization Expense		 0.20 0.66 0.20 0.47 0.47 0.09 0.37 0.36
Non-Cash Adjustments To Reconcile Net Income		 1.69 2.65 1.42 3.04 11 -7.52 28 12
Changes in Operating Assets and Liabilities, net		 -1.44 -2.61 2.22 -5.98 0.71 0.86 -3.17 5.10
Net Cash From Investing Activities		 -7.03 -4.42 -4.16 -8.23 -7.42 -0.25 -7.76 -173
Net Cash From Continuing Investing Activities		 -7.03 -4.42 -4.16 -8.23 -7.42 -0.25 -7.76 -173
Purchase of Property, Plant & Equipment		 -7.04 -4.45 -4.11 -8.17 -7.27 -0.12 -7.39 -9.66
Other Investing Activities, net		 0.00 0.03 -0.05 -0.07 -0.16 -0.14 -0.37 -0.00
Net Cash From Financing Activities		 116 -0.58 12 -1.88 -0.03 117 215 -0.19
Net Cash From Continuing Financing Activities		 116 -0.58 12 -1.88 -0.03 117 215 -0.19
Repurchase of Common Equity		 -3.22 - - 0.00 -1.90 -1.39 - -0.48
Other Financing Activities, net		 -1.02 -0.58 -0.26 -1.88 1.88 -1.65 20 0.30
Cash Interest Paid		 1.22 1.23 1.20 1.42 1.42 0.78 1.22 2.80
Cash Income Taxes Paid		 0.00 0.04 -0.13 -0.04 0.02 0.10 0.00 0.01

Annual Balance Sheets for Kestra Medical Technologies

This table presents Kestra Medical Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2025 2026
Period end date 4/30/2024 4/30/2025 4/30/2026
Total Assets		 46 296 358
Total Current Assets		 15 255 222
Cash & Equivalents		 8.25 238 100
Short-Term Investments		 - 0.00 97
Accounts Receivable		 2.00 8.08 15
Inventories, net		 3.29 6.57 6.71
Prepaid Expenses		 1.37 3.08 4.68
Plant, Property, & Equipment, net		 26 35 59
Total Noncurrent Assets		 4.94 5.59 77
Long-Term Investments		 - 0.00 66
Other Noncurrent Operating Assets		 4.94 5.59 11
Total Liabilities & Shareholders' Equity		 46 296 358
Total Liabilities		 78 90 99
Total Current Liabilities		 33 38 50
Accounts Payable		 24 24 27
Accrued Expenses		 9.08 14 23
Other Current Liabilities		 0.00 0.19 0.03
Total Noncurrent Liabilities		 45 52 48
Long-Term Debt		 43 41 43
Other Noncurrent Operating Liabilities		 2.71 11 5.79
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -209 205 260
Total Preferred & Common Equity		 0.00 205 260
Total Common Equity		 -209 205 260
Common Stock		 197 726 912
Retained Earnings		 -406 -520 -652
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.22
Noncontrolling Interest		 0.00 0.00 0.00

Quarterly Balance Sheets for Kestra Medical Technologies

This table presents Kestra Medical Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q3 2026
Period end date 7/31/2025 10/31/2025 1/31/2025 1/31/2026
Total Assets		 266 247 108 379
Total Current Assets		 221 195 70 314
Cash & Equivalents		 201 175 54 291
Accounts Receivable		 9.25 10 7.93 13
Inventories, net		 6.80 6.92 6.00 6.83
Prepaid Expenses		 3.43 2.66 1.64 3.20
Plant, Property, & Equipment, net		 40 46 31 54
Total Noncurrent Assets		 5.23 5.36 6.69 11
Other Noncurrent Operating Assets		 5.23 5.36 6.69 11
Total Liabilities & Shareholders' Equity		 266 247 108 379
Total Liabilities		 82 83 85 91
Total Current Liabilities		 32 36 39 43
Accounts Payable		 19 20 26 24
Accrued Expenses		 14 15 13 19
Other Current Liabilities		 0.04 0.05 - 0.01
Total Noncurrent Liabilities		 50 47 47 48
Long-Term Debt		 41 42 44 42
Other Noncurrent Operating Liabilities		 8.40 4.99 2.94 6.16
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 184 164 -258 288
Total Preferred & Common Equity		 184 164 -274 288
Total Common Equity		 184 164 -274 288
Common Stock		 730 743 194 901
Retained Earnings		 -546 -579 -468 -613

Annual Metrics And Ratios for Kestra Medical Technologies

This table displays calculated financial ratios and metrics derived from Kestra Medical Technologies' official financial filings.

Metric 2024 2025 2026
Period end date 4/30/2024 4/30/2025 4/30/2026
DEI Shares Outstanding		 - - 58,373,353.00
DEI Adjusted Shares Outstanding		 - - 58,373,353.00
DEI Earnings Per Adjusted Shares Outstanding		 - - -2.25
Growth Metrics		 - - -
Revenue Growth		 0.00% 115.05% 59.03%
EBITDA Growth		 0.00% -31.81% -21.92%
EBIT Growth		 0.00% -24.22% -21.05%
NOPAT Growth		 0.00% -25.06% -26.66%
Net Income Growth		 0.00% -20.92% -15.64%
EPS Growth		 0.00% -1.18% 52.63%
Operating Cash Flow Growth		 0.00% -7.44% -5.28%
Free Cash Flow Firm Growth		 0.00% 0.00% -54.28%
Invested Capital Growth		 0.00% 341.04% 350.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 6.13%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 1.30% 40.47% 51.37%
EBITDA Margin		 -272.15% -166.81% -127.88%
Operating Margin		 -305.83% -177.85% -141.64%
EBIT Margin		 -315.91% -182.47% -138.89%
Profit (Net Income) Margin		 -338.39% -190.28% -138.36%
Tax Burden Percent		 100.03% 100.12% 100.22%
Interest Burden Percent		 107.09% 104.16% 99.39%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -2,947.73% -1,362.70% -384.86%
ROIC Less NNEP Spread (ROIC-NNEP)		 -3,048.57% -1,314.18% -366.93%
Return on Net Nonoperating Assets (RNNOA)		 3,239.42% 1,231.23% 328.26%
Return on Equity (ROE)		 291.69% -131.47% -56.60%
Cash Return on Invested Capital (CROIC)		 0.00% -1,488.77% -512.15%
Operating Return on Assets (OROA)		 -191.23% -63.88% -40.39%
Return on Assets (ROA)		 -204.84% -66.62% -40.24%
Return on Common Equity (ROCE)		 1,892.75% 3.02% -56.60%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -60 -74 -94
NOPAT Margin		 -214.08% -124.49% -99.15%
Net Nonoperating Expense Percent (NNEP)		 100.84% -48.52% -17.93%
Return On Investment Capital (ROIC_SIMPLE)		 35.69% -30.21% -31.20%
Cost of Revenue to Revenue		 98.70% 59.53% 48.63%
SG&A Expenses to Revenue		 251.44% 192.15% 172.53%
R&D to Revenue		 55.69% 26.17% 20.48%
Operating Expenses to Revenue		 307.13% 218.32% 193.01%
Earnings before Interest and Taxes (EBIT)		 -88 -109 -132
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -76 -100 -122
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 2.88 4.32
Price to Tangible Book Value (P/TBV)		 0.00 2.88 4.32
Price to Revenue (P/Rev)		 7.26 9.89 11.80
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 204.65 44.34 22.52
Enterprise Value to Revenue (EV/Rev)		 14.86 6.60 9.49
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 -1.32 0.20 0.16
Long-Term Debt to Equity		 -1.32 0.20 0.16
Financial Leverage		 -1.06 -0.94 -0.89
Leverage Ratio		 -1.42 1.97 1.41
Compound Leverage Factor		 -1.53 2.06 1.40
Debt to Total Capital		 414.22% 16.67% 14.11%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 414.22% 16.67% 14.11%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1,724.71% 0.00% 0.00%
Common Equity to Total Capital		 -2,038.92% 83.33% 85.89%
Debt to EBITDA		 -0.56 -0.41 -0.35
Net Debt to EBITDA		 -0.45 1.97 1.80
Long-Term Debt to EBITDA		 -0.56 -0.41 -0.35
Debt to NOPAT		 -0.71 -0.55 -0.45
Net Debt to NOPAT		 -0.58 2.64 2.33
Long-Term Debt to NOPAT		 -0.71 -0.55 -0.45
Altman Z-Score		 -17.01 1.33 3.90
Noncontrolling Interest Sharing Ratio		 -548.89% 102.29% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.45 6.72 4.41
Quick Ratio		 0.31 6.47 4.19
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -81 -126
Operating Cash Flow to CapEx		 -590.83% -338.37% -234.16%
Free Cash Flow to Firm to Interest Expense		 0.00 -10.52 -16.63
Operating Cash Flow to Interest Expense		 -11.59 -10.03 -10.83
Operating Cash Flow Less CapEx to Interest Expense		 -13.56 -13.00 -15.45
Efficiency Ratios		 - - -
Asset Turnover		 0.61 0.35 0.29
Accounts Receivable Turnover		 13.92 11.87 8.41
Inventory Turnover		 8.34 7.22 6.97
Fixed Asset Turnover		 1.07 1.96 2.03
Accounts Payable Turnover		 1.15 1.49 1.81
Days Sales Outstanding (DSO)		 26.22 30.75 43.40
Days Inventory Outstanding (DIO)		 43.74 50.55 52.38
Days Payable Outstanding (DPO)		 317.67 245.28 202.20
Cash Conversion Cycle (CCC)		 -247.70 -163.98 -106.41
Capital & Investment Metrics		 - - -
Invested Capital		 2.02 8.91 40
Invested Capital Turnover		 13.77 10.95 3.88
Increase / (Decrease) in Invested Capital		 0.00 6.89 31
Enterprise Value (EV)		 413 395 903
Market Capitalization		 202 591 1,123
Book Value per Share		 ($10.53) $4.00 $4.45
Tangible Book Value per Share		 ($10.53) $4.00 $4.45
Total Capital		 10 247 302
Total Debt		 43 41 43
Total Long-Term Debt		 43 41 43
Net Debt		 34 -196 -220
Capital Expenditures (CapEx)		 12 23 35
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -26 -20 -24
Debt-free Net Working Capital (DFNWC)		 -18 217 172
Net Working Capital (NWC)		 -18 217 172
Net Nonoperating Expense (NNE)		 35 39 37
Net Nonoperating Obligations (NNO)		 34 -196 -220
Total Depreciation and Amortization (D&A)		 12 9.37 10
Debt-free, Cash-free Net Working Capital to Revenue		 -94.60% -33.84% -25.70%
Debt-free Net Working Capital to Revenue		 -64.95% 363.37% 180.80%
Net Working Capital to Revenue		 -64.95% 363.37% 180.80%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.13) ($2.43)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 24.58M 54.18M
Adjusted Diluted Earnings per Share		 $0.00 ($5.13) ($2.43)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 24.58M 54.18M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 51.35M 58.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -60 -74 -94
Normalized NOPAT Margin		 -214.08% -124.49% -99.15%
Pre Tax Income Margin		 -338.30% -190.05% -138.05%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -14.10 -14.11 -17.51
NOPAT to Interest Expense		 -9.56 -9.63 -12.50
EBIT Less CapEx to Interest Expense		 -16.07 -17.08 -22.13
NOPAT Less CapEx to Interest Expense		 -11.52 -12.59 -17.12
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -2.83% -1.87%

Quarterly Metrics And Ratios for Kestra Medical Technologies

This table displays calculated financial ratios and metrics derived from Kestra Medical Technologies' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q3 2026
Period end date 7/31/2024 10/31/2024 1/31/2024 7/31/2025 10/31/2025 1/31/2025 4/30/2025 1/31/2026
DEI Shares Outstanding		 - - - - - - 51,348,656.00 58,349,053.00
DEI Adjusted Shares Outstanding		 - - - - - - 51,348,656.00 58,349,053.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.83 -0.59
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -13 -13 -14 -20 -22 -14 -18 -24
Return On Investment Capital (ROIC_SIMPLE)		 - - - -8.96% -10.79% 6.73% -7.14% -7.37%
Earnings before Interest and Taxes (EBIT)		 -18 -19 -20 -26 -33 -21 -30 -34
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -17 -20 -24 -30 -21 -28 -34
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 -45 -53 -26 0.00 -51
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 0.00 0.00 24 31 12 8.91 39
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 24 31 12 0.00 27
Book Value per Share		 $0.00 $0.00 $0.00 $3.59 $3.19 ($13.78) $4.00 $4.94
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $3.59 $3.19 ($13.78) $4.00 $4.94
Total Capital		 0.00 0.00 0.00 226 206 66 247 330
Total Debt		 0.00 0.00 0.00 41 42 44 41 42
Total Long-Term Debt		 0.00 0.00 0.00 41 42 44 41 42
Net Debt		 0.00 0.00 0.00 -160 -134 -11 -196 -249
Capital Expenditures (CapEx)		 7.04 4.45 0.00 8.17 7.27 0.00 7.39 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 -13 -16 -23 -20 -20
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 188 160 31 217 271
Net Working Capital (NWC)		 0.00 0.00 0.00 188 160 31 217 271
Net Nonoperating Expense (NNE)		 6.98 6.97 7.66 5.61 11 7.34 16 9.83
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -160 -134 -11 -196 -249
Total Depreciation and Amortization (D&A)		 2.58 2.53 0.00 2.50 2.84 0.00 2.21 0.00
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.50) ($0.64) ($1.25) ($2.74) ($0.61)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 51.30M 51.38M 19.89M 24.58M 55.85M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.50) ($0.64) ($1.25) ($2.74) ($0.61)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 51.30M 51.38M 19.89M 24.58M 55.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 51.45M 58.35M 51.35M 51.35M 58.37M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -13 -14 -20 -22 -14 -18 -24
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Kestra Medical Technologies (NASDAQ: KMTS) has shown strong top-line growth over the last several quarters, but it remains a heavily loss-making and cash-burning company. The latest quarterly results suggest revenue momentum is improving, yet operating expenses are still far above gross profit, and the balance sheet has become more complex after large equity financing and preferred stock activity.

  • Revenue has expanded sharply year over year, with Q3 2026 revenue at $24.6 million versus $15.1 million in Q3 2025 and $8.3 million in Q3 2024.
  • Gross profit also improved meaningfully, rising to $12.9 million in Q3 2026 from $6.5 million a year earlier, showing better scale on the sales side.
  • Cash and equivalents remained high at $291.3 million in Q3 2026, giving the company a substantial liquidity cushion despite ongoing losses.
  • The company generated significant financing inflows in prior periods, including large equity and preferred equity raises, which helped support the balance sheet and fund operations.
  • PP&E investment continues, suggesting management is still building out the business infrastructure, with capital spending of $9.7 million in Q4 2026 and $7.4 million in Q4 2025.
  • The latest quarter available for the income statement is Q3 2026, while the latest cash flow and balance sheet data are Q4 2026 and Q3 2026, so the dataset is not perfectly aligned across all statements.
  • Interest income has been volatile, swinging from positive in some quarters to negative in Q4 2025, which may reflect changes in cash management or non-operating items.
  • Weighted average shares outstanding changed significantly over time, which means per-share comparisons may be affected by dilution and financing activity.
  • KMTS is still far from profitable. Q3 2026 net loss was $34.2 million, and Q4 2026 net loss widened to $38.8 million.
  • Operating losses remain large. In Q3 2026, operating income was a loss of $34.8 million, as SG&A of $42.7 million and R&D of $5.0 million overwhelmed gross profit.
  • Cash from operations was negative $18.7 million in Q4 2026, indicating the core business is still consuming cash.
  • Cash declined sharply in Q4 2026, with net cash change of negative $191.6 million, driven by operating losses and heavy investing activity.
  • Total liabilities were $91.4 million in Q3 2026, including $42.3 million of long-term debt, so the company carries meaningful financial obligations.
  • Common equity became much lower once redeemable noncontrolling interest and financing structure changes are considered in earlier periods, highlighting a complex and potentially risky capital structure.
  • Gross margin remains uneven and was even negative in some earlier quarters, such as Q4 2025, showing the business has not yet established consistent operating leverage.

Bottom line: Kestra Medical Technologies is growing fast, but the financial profile still looks like an early-stage, cash-intensive medical technology company. Investors will likely focus on whether revenue growth can continue to accelerate while SG&A and other operating costs start to come down as a percentage of sales. For now, the story is one of improving scale but persistent losses and cash burn.

07/21/26 01:47 PM ETAI Generated. May Contain Errors.

Kestra Medical Technologies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kestra Medical Technologies' fiscal year ends in April. Their fiscal year 2026 ended on April 30, 2026.

Kestra Medical Technologies' net income appears to be on an upward trend, with a most recent value of -$131.61 million in 2026, rising from -$94.12 million in 2024. The previous period was -$113.81 million in 2025. Check out Kestra Medical Technologies' forecast to explore projected trends and price targets.

Kestra Medical Technologies' total operating income in 2026 was -$134.74 million, based on the following breakdown:
  • Total Gross Profit: $48.86 million
  • Total Operating Expenses: $183.60 million

Over the last 2 years, Kestra Medical Technologies' total revenue changed from $27.81 million in 2024 to $95.13 million in 2026, a change of 242.0%.

Kestra Medical Technologies' total liabilities were at $98.81 million at the end of 2026, a 9.4% increase from 2025, and a 26.3% increase since 2024.

In the past 2 years, Kestra Medical Technologies' cash and equivalents has ranged from $8.25 million in 2024 to $237.60 million in 2025, and is currently $99.71 million as of their latest financial filing in 2026.

Over the last 2 years, Kestra Medical Technologies' book value per share changed from -10.53 in 2024 to 4.45 in 2026, a change of -142.2%.


Related Companies

Financial statements for NASDAQ:KMTS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel